Thomas Son

519 total citations
8 papers, 110 citations indexed

About

Thomas Son is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Thomas Son has authored 8 papers receiving a total of 110 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Thomas Son's work include Immunotherapy and Immune Responses (3 papers), CAR-T cell therapy research (2 papers) and Receptor Mechanisms and Signaling (2 papers). Thomas Son is often cited by papers focused on Immunotherapy and Immune Responses (3 papers), CAR-T cell therapy research (2 papers) and Receptor Mechanisms and Signaling (2 papers). Thomas Son collaborates with scholars based in United States and Sweden. Thomas Son's co-authors include Stefania Risso Bradley, Robert E. Davis, Hans H. Schiffer, Tracy A. Spalding, Jelveh Lameh, Thomas Ott, Ali Tabatabaei, Douglas W. Bonhaus, Derek Nguyen and Ethan S. Burstein and has published in prestigious journals such as Cancer Research, Journal of Pharmacology and Experimental Therapeutics and Neuropharmacology.

In The Last Decade

Thomas Son

7 papers receiving 108 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Son United States	4	68	58	19	18	14	8	110
Charlotte Avet Canada	6	166 2.4×	104 1.8×	19 1.0×	8 0.4×	4 0.3×	10	235
Louis Dwomoh United Kingdom	7	84 1.2×	56 1.0×	3 0.2×	14 0.8×	15 1.1×	8	123
Shahzina Kanwal China	8	129 1.9×	15 0.3×	5 0.3×	8 0.4×	9 0.6×	10	250
Thomas Bajaj Germany	6	73 1.1×	8 0.1×	28 1.5×	10 0.6×	3 0.2×	10	171
Juan C. Troncoso United States	3	103 1.5×	15 0.3×	4 0.2×	12 0.7×	30 2.1×	4	168
Shelley Sheridan United States	3	191 2.8×	43 0.7×	3 0.2×	15 0.8×	30 2.1×	3	246
Anne Kinhult Ståhlbom Sweden	7	38 0.6×	12 0.2×	15 0.8×	5 0.3×	33 2.4×	10	135
Yayoi Nozaki Japan	6	108 1.6×	23 0.4×	6 0.3×	4 0.2×	5 0.4×	8	167
Luke Jehu United Kingdom	7	131 1.9×	32 0.6×	6 0.3×	23 1.3×	18 1.3×	7	227
Cristiana Artiola Italy	9	143 2.1×	49 0.8×	15 0.8×	4 0.2×	10 0.7×	11	315

Countries citing papers authored by Thomas Son

Since Specialization

Citations

This map shows the geographic impact of Thomas Son's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Son with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Son more than expected).

Fields of papers citing papers by Thomas Son

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Son. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Son. The network helps show where Thomas Son may publish in the future.

Co-authorship network of co-authors of Thomas Son

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Son. A scholar is included among the top collaborators of Thomas Son based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Son. Thomas Son is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Brown, Jennifer G., Thomas Son, Linda X. Jin, et al.. (2024). Abstract 1904: Preclinical development of MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3 for solid cancer. Cancer Research. 84(6_Supplement). 1904–1904. 3 indexed citations

Brown, Jennifer G., Thomas Son, Linda X. Jin, et al.. (2024). Abstract 1897: Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers. Cancer Research. 84(6_Supplement). 1897–1897. 1 indexed citations

Chen, Francine Z., Anushka De Costa, Ying Li, et al.. (2022). Abstract 330: Targeting B7-H3 in prostate cancer: Preclinical proof of concept with MGC018, an investigational anti-B7-H3 antibody-drug conjugate. Cancer Research. 82(12_Supplement). 330–330. 1 indexed citations

Son, Thomas, Jeff Hooley, Ying Li, et al.. (2020). Abstract 5203: MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3, exhibits immunomodulatory activity and enhanced antitumor activity in combination with checkpoint inhibitors. Cancer Research. 80(16_Supplement). 5203–5203. 3 indexed citations

Loo, Deryk, Thomas Son, Jeff Hooley, et al.. (2016). Abstract 1201: Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer. Cancer Research. 76(14_Supplement). 1201–1201. 2 indexed citations

Bradley, Stefania Risso, Jelveh Lameh, Linda Ohrmund, et al.. (2009). AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology. 58(2). 365–373. 60 indexed citations

Piu, Fabrice, Luis R. Gardell, Thomas Son, et al.. (2007). Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. The Journal of Steroid Biochemistry and Molecular Biology. 109(1-2). 129–137. 22 indexed citations

Vanover, Kimberly E., Scott C. Harvey, Thomas Son, et al.. (2004). Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist. Journal of Pharmacology and Experimental Therapeutics. 310(3). 943–951. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact